Summary by Futu AI
On January 28, 2024, Panbela Therapeutics, Inc. announced the entry into a material definitive agreement with Roth Capital Partners, LLC, acting as the Placement Agent, and certain purchasers. The agreement pertains to a registered public offering of approximately $9.0 million, which includes 794,000 shares of common stock and pre-funded warrants to purchase up to 3,581,000 shares, as well as Class E and Class F common stock purchase warrants to purchase up to an aggregate of 8,750,000 shares of common stock. The offering price is set at $2.06 per share of common stock and associated common warrants, or $2.059 per pre-funded warrant and associated common warrants. The public offering is expected to close on January 31, 2024, subject to customary closing conditions. The common warrants are exercisable upon issuance...Show More